카르바페넴 시장 : 약제 클래스별, 용도별, 유통 채널별 - 세계 예측(2024-2032년)

Global Carbapenem Market is set to achieve a 5% CAGR from 2024 to 2032, driven by increasing healthcare demands. The World Health Organization (WHO) reports that the global population aged 60 and above is projected to nearly double from 12% in 2015 to 22% by 2050. By then, 80% of older individuals will reside in low- and middle-income countries. This aging demographic is more prone to chronic conditions and infections, escalating the need for effective antibiotics such as carbapenems.

In addition, the high prevalence of Hospital-Acquired Infections further contributes to the market growth as Carbapenems are often used to treat severe hospital-acquired infections.

The overall Carbapenem Market is segmented based on drug class, application, distribution channel, and region.

The Imipenem segment will experience substantial growth over 2024-2032. Pharmaceutical companies are focusing on this drug class to address severe bacterial infections. Imipenem's broad-spectrum activity and efficacy against resistant strains make it crucial in treating life-threatening conditions. Enhanced production capabilities and stringent regulatory compliance ensure high-quality imipenem supply, meeting the rising demand for potent antibiotics in healthcare settings.

The Bloodstream infections application segment will capture a significant Carbapenem market share by 2032. Bloodstream infections require immediate and effective treatment to prevent severe complications and mortality. Carbapenems, including imipenem, play a critical role in managing these infections due to their broad-spectrum antibacterial properties. Increased prevalence of bloodstream infections, particularly in hospital settings, drives the adoption of carbapenems. Advances in diagnostic technologies and healthcare infrastructure further support market growth by enabling timely and accurate infection management.

Asia Pacific carbapenem market will drive commendable gains throughout 2024-2032 due to rapid urbanization, increasing healthcare expenditures, and a high prevalence of infectious diseases. Well-established healthcare systems, significant investment in medical research, and robust regulatory frameworks ensure the quality and safety of pharmaceutical products. Government support for healthcare initiatives and the presence of leading pharmaceutical companies in the region drive innovation and production, contributing to the strong growth of the carbapenem market in Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of antibiotic-resistant infections
    • 3.2.1.2 High R&D investments in clinical research
    • 3.2.1.3 Growing incidence of hospital-acquired infections
    • 3.2.1.4 Increased awareness and diagnostic advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of production of carbapenem-based antibiotics
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Meropenem
• 5.3 Imipenem
• 5.4 Ertapenem
• 5.5 Doripenem
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Urinary tract infections
• 6.3 Bloodstream infections
• 6.4 Intra-abdominal infections
• 6.5 Bacterial meningitis
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca PLC
• 9.2 Aurobindo Pharma
• 9.3 Daewoong Pharmaceuticals Co., Ltd.
• 9.4 F. Hoffmann-La Roche Ltd.
• 9.5 Johnson & Johnson
• 9.6 Kopran Limited
• 9.7 Lupin Limited
• 9.8 Merck & Co., Inc.
• 9.9 Novartis AG
• 9.10 Pfizer Inc.
• 9.11 Shenzhen Haibin Pharmaceutical Co. Ltd.
• 9.12 Sun Pharmaceutical Industries Ltd.
• 9.13 The Menarini Group
• 9.14 Venus Remedies Ltd.
• 9.15 Viatris Inc.